SCHEMBL1500192

SCHEMBL1500192

Nc1cc(Br)ccc1C(=O)NCc1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.74
KMT2A Q03164 2/20 0.74
NSD2 O96028 2/20 0.57
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 3/20 0.54
HSD17B10 Q99714 1/20 0.53
PKM P14618 1/20 0.52
GAA P10253 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
USP2 O75604 1/20 0.50
APEX1 P27695 1/20 0.50
METAP2 P50579 1/20 0.50
CHRNB2 P17787 1/20 0.50
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA4 P43681 1/20 0.50
TP53 P04637 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20145565 0.82 HPGD (0.74) HPGDKMT2AKDM4EALDH1A1HSD17B10
SCHEMBL10323669 0.82 HPGD (0.69) HPGDKMT2ANSD2KDM4EALDH1A1
SCHEMBL20145424 0.82 KMT2A (0.74) HPGDKMT2AALDH1A1PKMGAA
SCHEMBL4500866 0.82 HPGD (0.64) HPGDKMT2ANSD2KDM4EALDH1A1
SCHEMBL28728994 0.82 HPGD (0.73) HPGDKMT2ANSD2KDM4EALDH1A1
SCHEMBL2236766 0.81 HPGD (0.77) HPGDKMT2ANSD2KDM4EALDH1A1
SCHEMBL17241555 0.80 AKR1B1 (0.62) HPGDKMT2AKDM4EALDH1A1GAA
SCHEMBL17241588 0.80 KMT2A (0.51) HPGDKMT2AKDM4EALDH1A1L3MBTL1
SCHEMBL21296258 0.79 HPGD (0.69) HPGDKMT2AALDH1A1PKMGAA
SCHEMBL29092475 0.79 KMT2A (0.69) HPGDKMT2AALDH1A1PKMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3063143-B1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2018-05-16 EP disclosed
US-20110160208-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-30 US disclosed
US-7902369-B2 Diaryl-substituted five-membered heterocycle derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
US-20070173507-A1 Dairyl-substituted five-membered heterocycle derivative MSD K.K. (JP) 2007-07-26 US disclosed
CN-1934094-A Diaryl substituted heterocyclic 5-membered ring derivatives BANYU PHARMA CO LTD (JP) 2007-03-21 CN disclosed
EP-1726585-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160208-A1 DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE OPRK1, GRM1, GRIK1 HPGD 923/4885KMT2A 3671/4885NSD2 2924/4885
US-20070173507-A1 Dairyl-substituted five-membered heterocycle derivative OPRK1, OPRL1, GRM1 HPGD 918/4885KMT2A 4006/4885NSD2 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.